Hearing Loss Secondary to TECTA Gene Mutations
Annals of Otology, Rhinology & Laryngology · 2025
DOI: 10.1177/00034894251315550 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Otology, Rhinology & Laryngology, 2025. Verfasst von Rocío González-Aguado und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain. Hauptthemen laut MEDLINE: Hearing Loss, Sensorineural, Extracellular Matrix Proteins, Hearing Loss, Bilateral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
To assess the prevalence and clinical characterization of variants in the TECTA gene among individuals with bilateral sensorineural hearing loss of unknown etiology in northern Spain.
Methods
A 6-year (2018-2024) observational, prospective, and descriptive study was conducted on patients with bilateral sensorineural hearing loss at a tertiary hospital. Next generation sequencing using a gene panel for sensorineural hearing loss was performed to detect pathogenic, likely pathogenic, or variants of unknown significance in the TECTA gene.
Results
Among 326 patients, pathogenic or likely pathogenic TECTA variants were found in 7 patients (2.14%), including c.3107G>A (n = 6) and c.5383+6T>A (n = 1). Variants of unknown significance were found in 8 patients (2.45%). About 14 of 15 probands had a family history of hearing loss with autosomal dominant inheritance. Eight relatives with confirmed pathogenic variants were also included, totalling 23 cases. Six patients with pathogenic variants and 3 with variants of unknown significance had moderate mid-frequency hearing loss, while others had severe high-frequency loss. Hearing loss was typically progressive, ranging from congenital onset to the fifth decade. Most were treated with hearing aids; none required cochlear implants.
Conclusions
TECTA gene variants are relatively common in this population, with c.3107G>A being the most frequent. The typical phenotype is slowly progressive, mid-to-high frequency sensorineural hearing loss, often starting in childhood and usually requiring hearing aids fitting with good results in improving speech intelligibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
- Faculty of Medicine, University of Cantabria, Santander, Cantabria, Spain.
- Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.
- Department of Genetics, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
- Cellular Signaling and Therapeutic Targets in Cancer, Laboratory, Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.
- Servicio de Radiodiagnóstico, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
ORCID-Profile: Carmelo Morales-Angulo
Zitieren
APA
González-Aguado, R., Onecha, E., Gallo-Terán, J., & Morales-Angulo, C. (2025). Hearing Loss Secondary to TECTA Gene Mutations. Annals of Otology, Rhinology & Laryngology. https://doi.org/10.1177/00034894251315550
Vancouver
González-Aguado R, Onecha E, Gallo-Terán J, Morales-Angulo C. Hearing Loss Secondary to TECTA Gene Mutations. Annals of Otology, Rhinology & Laryngology. 2025. doi:10.1177/00034894251315550
BibTeX
@article{GonzlezAguado2025,
author = {González-Aguado, Rocío and Onecha, Esther and Gallo-Terán, Jaime and Morales-Angulo, Carmelo},
title = {Hearing Loss Secondary to TECTA Gene Mutations},
journal = {Annals of Otology, Rhinology & Laryngology},
year = {2025},
doi = {10.1177/00034894251315550}
}
EUVIMED